It’s early, not even 7 a.m., in fact, and the above statement is prefaced with an apology for interrupting the free-flowing dialogue taking place between a gathering of five biopharmaceutical executives on day two of the 2020 J.P. Morgan Healthcare Conference (JPM). Among the incessant ringing of nearby cell phones, conversations, and the echo of […]

A small molecule inhibitor being developed for hereditary angioedema (HAE) treatment, called PHA121, was as effective as Firazyr (icatibant acetate) — an approved therapy with a similar mechanism of action — at reversing bradykinin-induced changes in blood pressure in monkeys, results of a preclinical study show. Pharvaris‘s oral investigative treatment also exerted an effect on blood pressure faster than Firazyr in […]

A pair of good-news items from Chimerix Inc. pushed the Durham, N.C.-based company’s stock (NASDAQ:CMRX) to $2.15, closing up 64 cents, or 42%, higher as backers reacted to near-term NDA plans for smallpox countermeasure brincidofovir (BCV) and the start of a phase II/III trial with dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI). CEO Mike Sherman said the […]